Compensation in Pancreatic β-Cell Function in Subjects With Glucokinase Mutations

The relationship between the in vivo insulin secretory responsiveness of the pancreatic β-cell to glucose and the flux of glucose through the enzyme glucokinase was investigated in six subjects with heterozygous glucokinase mutations and in six matched control subjects. This was done by combining data published previously on the in vivo dose-response relationships between glucose and insulin secretion and on the in vitro enzymatic properties of wild-type and mutant forms of glucokinase. The flux of glucose through glucokinase (GK flux) in these subjects was estimated using a model based on the approximate Michaelis-Menten kinetics of wild-type and mutant forms of the enzyme. In two subjects with glucokinase mutations, which resulted in only a small reduction in enzymatic activity, the decrease in insulin secretion was directly proportional to the decrease in GK flux predicted using a Michaelis-Menten model for both mutant and wild-type glucokinase. However, in four subjects with glucokinase mutations, which resulted in severe reductions in enzymatic activity, insulin secretion was reduced compared with control subjects but less than predicted. This latter result implies the existence of a compensatory change in the β-cells of such subjects, which results in a relative increase in insulin secretory response. We propose modifications to the simple model relating glucose concentration and GK flux, including glucose-induced overexpression of the normal allele and a role of glucokinase regulatory protein. The modifications take into account the possibility that the degree of compensation may be directly related to the severity of the mutation.

[1]  K. Clément,et al.  Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. , 1994, The Journal of clinical investigation.

[2]  J. Beckmann,et al.  Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. , 1993, The New England journal of medicine.

[3]  A. Hattersley,et al.  Glucokinase mutations associated with non-insulin-dependent (type 2) diabetes mellitus have decreased enzymatic activity: implications for structure/function relationships. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Magnuson,et al.  Concordant Glucose Induction of Glucokinase, Glucose Usage, and Glucose-Stimulated Insulin Release in Pancreatic Islets Maintained in Organ Culture , 1992, Diabetes.

[5]  A. Hattersley,et al.  Linkage of type 2 diabetes to the glucokinase gene , 1992, The Lancet.

[6]  A. Joyner Gene targeting and gene trap screens using embryonic stem cells: New approaches to mammalian development , 1991, BioEssays : news and reviews in molecular, cellular and developmental biology.

[7]  M. Magnuson Glucokinase Gene Structure: Functional Implications of Molecular Genetic Studies , 1990, Diabetes.

[8]  C. Ucla,et al.  Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Bruce H. Frank,et al.  Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. , 1986, The Journal of clinical investigation.

[10]  F. Matschinsky,et al.  New perspectives on pancreatic islet glucokinase. , 1984, The American journal of physiology.

[11]  H. Kuzuya,et al.  Characterization of Seven C-peptide Antisera , 1978, Diabetes.

[12]  A. Lazarow,et al.  Immunoassay of Insulin: Two Antibody System: Plasma Insulin Levels of Normal, Subdiabetic and Diabetic Rats , 1963, Diabetes.